Clinical Guidelines
Commentary & Perspectives
Feature

Inside the Race to Detect Neurodegenerative Disease Early

Unlocking a new frontier in diagnosing and understanding complex brain diseases long before symptoms appear

Share

Advancements in neurodegenerative disease diagnostics play a crucial role in enhancing patient outcomes. Amprion, led by CEO Russ Lebovitz, has shifted its focus from Creutzfeldt-Jakob disease to developing diagnostics for prevalent conditions like Parkinson's and Huntington's disease. Their SAAmplify-αSyn test has shown remarkable accuracy, detecting biomarkers years before clinical diagnosis. This innovation could also pave the way for broader applications in Huntington’s diagnostics, employing protein misfolding assays to improve mutation detection and treatment precision.

Original Source(s)

Inside the Race to Detect Neurodegenerative Disease Early

Unlocking a new frontier in diagnosing and understanding complex brain diseases long before symptoms appear

  • by Jessica Allerton

  • November 27, 2025

  • 6 min

Related Content

FDA OKs First SMA Gene Replacement Therapy

The FDA approved Itvisma, the first gene replacement therapy for children 2 years and older, teens, and adults with spinal muscular atrophy, a one-time treatment that replaces the SMN1 gene and demonstrated improved motor function in Phase 3 studies.

Brain Shifts at Hidden Ages 

Manifold analysis reveals distinct organizational epochs separated by turning points at ages 9, 32, 66, and 83 years across 4,216 diffusion imaging scans.

Brain Stimulation Boosts Vision Recovery

Cross-frequency tACS combined with visual training significantly improved motion discrimination and expanded visual fields in chronic hemianopia patients.